Sign in

    Andre Uddin • Research Capital

    Andre Uddin is a Managing Director and Senior Equity Analyst at Research Capital, specializing in healthcare sector research with a coverage focus on major biopharmaceutical and life sciences companies. He has delivered a success rate of 46% across 217 ratings, generating an average return of +35.40%, with the majority of his recommendations being BUY ratings. Uddin holds a prominent overall analyst ranking (currently 390 on TipRanks), reflecting his consistent track record and expertise, and he is regularly featured in key company earnings calls. His career at Research Capital is complemented by deep industry experience and recognized professional credentials, though specific securities licenses or FINRA registrations are not publicly listed.

    Andre Uddin's questions to Theratechnologies Inc (THTX) leadership

    Andre Uddin's questions to Theratechnologies Inc (THTX) leadership • Q1 2025

    Question

    Andre Uddin of Research Capital Corporation inquired about Theratechnologies' business development strategy, specifically whether the company is targeting products in its current therapeutic areas and if it would consider acquiring an already-approved drug versus in-licensing a late-stage candidate.

    Answer

    President and CEO Paul Lévesque responded that the company's priority is to pursue accretive, late-stage assets with a high probability of approval that can create synergies with its existing commercial infrastructure. Global Commercial Officer John Leasure added that while they are also evaluating on-market assets, those opportunities are more complex to find.

    Ask Fintool Equity Research AI

    Andre Uddin's questions to Theratechnologies Inc (THTX) leadership • Q3 2024

    Question

    Inquired about the business development strategy, plans for a backup EGRIFTA facility, clarification on the FDA's PAS review timeline, and the expected release of final data for TH1902.

    Answer

    The company is looking for accretive assets in the U.S. and Canada and is open to various deal structures. They do not plan to set up a backup facility for EGRIFTA, opting instead to build up inventory with the new F8 formulation's manufacturer. They are confident the FDA will accelerate the PAS review to avoid a drug shortage. Final data for the TH1902 trial is expected towards the end of the 2024 calendar year.

    Ask Fintool Equity Research AI

    Andre Uddin's questions to Theratechnologies Inc (THTX) leadership • Q3 2024

    Question

    Andre Uddin of Research Capital asked about the criteria for new portfolio products, plans for a backup manufacturing facility for EGRIFTA, the expected FDA review time for the PAS filing, and the timeline for final data from the TH1902 trial.

    Answer

    CEO Paul Lévesque explained they are seeking innovative, accretive products in the U.S. and Canada that challenge the standard of care, considering both in-licensing and acquisitions. CFO Philippe Dubuc stated a backup facility is not planned; instead, they will build a large inventory of the new F8 formulation, which has a different manufacturer. Mr. Lévesque expressed confidence the FDA would expedite the PAS review to avoid a patient-level shortage. Chief Medical Officer Dr. Christian Marsolais indicated that final data for TH1902 would likely be available towards the later part of 2024.

    Ask Fintool Equity Research AI